What's in China National Biotec Group Company Limited's pipeline?

China National Biotec Group Company Limited has 15 drugs in our index: 15 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with China National Biotec Group Company Limited's portfolio?

Top competitors by shared drug class: Sinovac Biotech Co., Ltd, GlaxoSmithKline, Merck Sharp & Dohme LLC, Sanofi Pasteur, a Sanofi Company, Jiangsu Province Centers for Disease Control and Prevention.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/china-national-biotec-group-company-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

China National Biotec Group Company Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

China National Biotec Group Company Limited pipeline: 15 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
IIV4+PPV23	IIV4+PPV23	marketed		Other
COVAX+PPV23;COVAX+IIV4	COVAX+PPV23;COVAX+IIV4	marketed		Immunology
COVAX	COVAX	marketed		Other
Sabin-IPV and DTaP	Sabin-IPV and DTaP	marketed
Inactivated Polio Vaccine	Inactivated Polio Vaccine	marketed
HepA	HepA	marketed
sIPV+DTaP+MMR	sIPV+DTaP+MMR	marketed	Combination vaccine	Immunology / Infectious Disease Prevention
IIV4 and PPV23	IIV4 and PPV23	marketed	vaccine	Immunology
COVAX+IIV4; COVAX+PPV23	COVAX+IIV4; COVAX+PPV23	marketed	vaccine combination	Immunology / Infectious Disease
EV71 vaccine and influenza vaccine	EV71 vaccine and influenza vaccine	marketed	vaccine	Immunology / Infectious Disease
coadministration	coadministration	marketed		Other
sIPV+DTaP+HepA	sIPV+DTaP+HepA	marketed	Combination vaccine	Immunology / Infectious Disease Prevention

Therapeutic area mix

Immunology / Infectious Disease · 4
Immunology · 3
Other · 3
Immunology / Infectious Disease Prevention · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sinovac Biotech Co., Ltd · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Sanofi Pasteur, a Sanofi Company · 4 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 4 shared drug classes
Pfizer · 3 shared drug classes
Sanofi · 3 shared drug classes
Boryung Pharmaceutical Co., Ltd · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for China National Biotec Group Company Limited:

Cite this brief

Drug Landscape (2026). China National Biotec Group Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/china-national-biotec-group-company-limited. Accessed 2026-05-17.